First Assay Results Reported for the Trapper Zone Following Completion of the 2025 Phase of the Mineral Resource Estimate ...
First Assay Results Reported for the Trapper Zone Following Completion of the 2025 Phase of the Mineral Resource Estimate ...
Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs ...